DD
Therapeutic Areas
Alterity Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ATH434 | Multiple System Atrophy (MSA) | Phase 2 |
| Discovery MPACs | Neurodegenerative Diseases (e.g., Tauopathies) | Discovery |
Leadership Team at Alterity Therapeutics
DS
David Stamler, M.D.
Chief Executive Officer
GK
Geoffrey Kempler
Non-Executive Chairman
AM
Andrew M. Saik
Chief Financial Officer & Company Secretary
DR
Dr. Rebecca L. Wood-Horrill
Vice President, Clinical Development
DS
Dr. Steven Gourlay
Chief Medical Officer